Skip to main content

Social risk analytics: The right data for the right interventions

All forward-thinking hospitals understand the role of social risk in providing effective, equitable and efficient care. In many ways, hospital objectives align with those of social risk assessment. Both help to distinguish acute from long-term needs, identify underlying contributors to poor outcomes, and, wherever possible, help minimize or completely prevent more serious interventions.

Six social risk factors and their drivers

Social risk is a measure of vulnerability as defined by specific social determinants of health. DataGen uses the following six SDOH categories.

Social Determinants of Health


Defined by

Individual risk drivers

Community risk influencers


Access, affordability and literacy




Strength, resources and resiliency

Financial assets, liabilities and opportunities

Income, cost of living and opportunity


Sufficient access and affordability

Healthy foods and food literacy


Health literacy

Healthcare access, navigation, comprehension and adherence

Culture, demographics and education



Standard of living

Stability, quality and crowding

Same + overall affordability


Adequacy related to healthcare

Access, proximity and mobility

Access and proximity

Each category includes drivers that help calculate social risk (none to high) and prioritize need. Numerous data points and sources for each social determinant can help hospitals design interventions that transition individuals and communities from struggling to thriving.

The importance of an analytics-informed approach

Measuring social risk is new to most healthcare stakeholders. An analytics-informed approach — in addition to community partnerships — is needed to accurately identify, prioritize, measure and evaluate SDOH interventions. Such an approach also requires SDOH-specific data that are diverse, granular to the sub-ZIP code level and can be integrated with existing EHR and claims data. The result is empowered understanding for measurable return on investment, one of the most difficult SDOH objectives to achieve.

Three DataGen advantages make us the ideal social risk analytics partner:
  • First, we understand the unique needs of hospitals and health systems.
  • Second, we are able to license market-leading SDOH data and analytics from our partner, Socially Determined.
  • Third, our data and capabilities free up resources by integrating Socially Determined’s social metrics with your data for new and powerful insights.
These combined resources deliver a unique brand of social determinants telescoping — the ability to literally zoom in and out on healthcare needs, risks and the best responses for evidence-based ROI.

Three social risk advantages

Measuring social risk is vital to providing the right help to the right people at the right time. Social risk analytics are also the perfect companion to the Community Health Needs Assessment and can strengthen collaboration between hospitals and the growing list of partners needed to address CHNA findings. In addition, a new standard of care is emerging that links health equity to advanced payment models.

Providers must be prepared.

A recent DataGen poll showed that more than 20% of health systems are not yet involved in SDOH activities. Among those that are, measuring results and ROI is one of the biggest challenges, yet many providers have not yet moved beyond claims data or determined how to best analyze the limited information they have.

Now is the time for providers to choose empowerment through a wealth of new SDOH data and analytics. Individuals at risk and the communities they call home are counting on it.


Popular posts from this blog

BPCI Advanced – take advantage of the model extension now

The Bundled Payment for Care Improvement (BPCI) Advanced Model is now open for applications until May 31, 2023. This model provides a unique opportunity to acute care hospitals and physician group practices who are looking to: evaluate their bundle performance; rejoin if they have previously dropped out due to being under a convener; or take advantage of the changes to the model. With a small window to sign the participation agreement, you’ll need experts to process data quickly and accurately for evaluation. BPCI Advanced Program Details The Centers for Medicare & Medicaid Services (CMS) announced in October 2022 that this program will extend from January 2024 to December 2025. Data used for evaluation will be taken from the baseline period between October 2018 and September 2022. A participation agreement will be sent out in September 2023 and needs to be signed by October 2023 in order to participate. Those who apply before the May 31 deadline will benefit

BPCI Advanced Model Extension

CMS recently made several major announcements about the Bundled Payments for Care Improvement Advanced Model.  The model, which was due to expire at the end of 2023 (Model Year 6), will be extended for an additional two years through Dec. 31, 2025.  New applications will be accepted in 2023 for the two-year extension. Participants still active in Model Year 6 can continue without reapplying by signing an amended and restated participation agreement for Model Year 7.  New methodological changes will be implemented for Model Year 6, which starts on Jan. 1, 2023. Methodological changes include that: the CMS Discount Factor for medical clinical episodes will be reduced from 3% to 2%;  the Peer Group Trend Factor Adjustment cap for all clinical episodes will be reduced from 10% to 5%; the Major Joint Replacement of the Upper Extremity clinical episode category will become a multi-setting episode category by allowing episodes to be triggered when the procedure is performed in the hospital ou

You’ve been accepted to the Enhancing Oncology Model. Now what?

The Centers for Medicare and Medicaid Services Innovation Center recently announced approved applicants for the new Enhancing Oncology Model. If your facility has been selected by CMS, are you still weighing your options during the current baseline evaluation period?  Two deciding factors may include the program data that CMS provides and whether EOM is enough of an improvement over the prior Oncology Care Model to make your investment worthwhile. Another factor to consider: Will you have the resources in place to conduct a baseline evaluation before EOM’s program start on July 1, 2023? How EOM differs from OCM EOM aims to improve the coordination of oncology care, drive practice transformation and reduce Medicare fee-for-service spending through episode-based payment. It includes three major updates: Fewer cancer types. Compared with OCM’s 21, EOM will be limited to seven common cancer types: breast, prostate, lung, small intestine/colorectal, multiple myeloma, lymphoma and chronic le